Dyslipidemia

Marc Bonaca, MD discusses the personalization of treatment in PAD patients, lack of proper research into the condition, and optimizing delivery of care.

Peter Toth, MD discusses the combination treatment aspects of lipid management agents, as well as the effect of the COVID-19 pandemic on cardiovascular care.

Peter Toth, MD, discusses the movement towards new agents in treatment of lipid management.

There are several cholesterol lowering drugs available for this patient population.

An analysis of data from the COMPASS study suggests the addition of low-dose rivaroxaban to aspirin resulted in benefits, irrespective of concomitant therapies or comorbidities.

Novartis announced the Complete Response resubmission for inclisiran in a statement on July 6, 2021.

An analysis of data from an RCT suggests statin use does not negatively impact the neurocognitive health or memory of older patients.

The FDA has granted approval to dabigatran etexilate (Pradaxa) for treatment of blood clots in pediatric patients with VTE and prevention of recurrent blood clots in those who have completed treatment for VTE.

Analysis of 2-year data from the GOULD Registry indicates new strategies are needed to address the suboptimal levels of lipid-lowering therapy intensification among patients with ASCVD and increased LDL-C.

The AHA has released a scientific statement highlighting the importance of prescribing physical activity as a first-line treatment in patient populations with elevated blood pressure or elevated cholesterol.

An analysis of patient and clinician responses to surveys within BOAT-AF suggests many were willing to consider DOACs but were never prescribed anticoagulation and also provides insight into how trends in this cohort compared to those in the ACC's PINNACLE registry.

A pooled risk simulation of phase 3 data of bempedoic acid suggests the first-in-class ATP citrate lyase inhibitor could reduce risk of cardiovascular events in patients with established cardiovascular disease and elevated LDL-C.

The TALOS AMI study suggests DAPT de-escalation 30 days after PCI was associated with lower rates of bleeding and the study's composite endpoint of cardiovascular death, MI, or stroke.

As part of our coverage of ACC.21, Practical Cardiology reached out to Deepak Bhatt, MD, MPH, to learn about his reaction to the latest analysis of the STRENGTH trial and how it might impact how REDUCE-IT results are interpreted.

A secondary analysis of the STRENGTH trial from ACC.21 is calling into question the apparent CV benefits of other fish oil-based agents in patients with elevated triglycerides.

The ADAPTABLE study from DCRI suggests patients with existing CVD saw similar outcomes whether they were receiving 81 mg or 325 mg aspirin, but also suggests patients with the higher dose were more likely to discontinue therapy.

There was no significant association between uric acid levels and incident stroke.

The latest study from Penn Medicine's Nudge Unit is detailing the impact of time of appointment on the probability of receiving a prescription for statin therapy at primary care clinics among patients with an indication for statin therapy.

In this column, Dr. Paul Thompson provides an account of a recent conversation with a colleague related to the potential for tendon issues, including tendon rupture, in a patient on statin therapy.

Bempedoic acid monotherapy and its combination with ezetimibe for lipid lowering in patients intolerant to statins.

Role of dietary and lifestyle modifications as part of lipid management.

Dr. Paul Thompson reflects on the results of recent N-of-1 studies examining the effects of statin therapy on muscle pain and offers his perspective on the conclusions drawn by these trials.

Dean Karalis, MD, provides expertise on the appropriate use of statins based on primary and secondary prevention.

Expert cardiologists express support for the uptake in the use of inclisiran once approved based on the cost-effectiveness.

The American Heart Association and American Stroke Association have released a special report related to the treatment of blood clots or low platelet counts related to the COVID-19 vaccine, which has garnered mass amounts of attention despite being a rare complication.